Healthcare Industry News: dialysis
News Release - February 19, 2016
Nipro Medical Corporation Launches the Cronus(TM) HP 0.035" OTW PTA Balloon Catheter in the United StatesBRIDGEWATER, N.J., Feb. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Nipro North America, a division of Nipro Medical Corporation, announced the launch of the Cronus HP high-pressure, 0.035" over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter.
Cronus HP is indicated for percutaneous transluminal angioplasty in the femoral, popliteal, iliac and renal arteries and for the treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae. This is the latest product offering from Nipro's Interventional Division that will see a number of further innovative medical technology launches throughout 2016 and 2017.
Cronus HP achieves an average rated burst pressure of 26 atmospheres across the entire size matrix. This semi-compliant balloon provides unparalleled flexibility at high pressure, while minimizing balloon elongation and "dog bone" effect. The combination of high pressure, flexibility and durability allow Nipro to deliver a product that addresses the limitations of conventional high pressure PTA balloons. Cronus HP is intended to treat AVF stenoses ranging from simple, focal, venous outflow strictures to more complex juxta-anastomotic obstructions in early fistula failures.
"Cronus HP provides physicians with a high-pressure PTA balloon catheter, specifically designed to successfully balloon the most resilient stenoses that are typically resistant to expansion, while being flexible enough to conform to natural vasculature of native fistulae. This is particularly important at and across the anastomosis, where less vessel straightening leads to minimal vascular damage and superior outcomes," said John O'Connor, National Sales Manager for Nipro's Interventional Division.
Cronus HP features laser bonding at critical flex points and low profiles along its catheter shaft, which help achieve superior trackability and pushability over guidewires. In addition, its tri-fold pleat technology allows for crossability in highly stenosed lesions and enhanced re-cross whenever multiple inflations might be required in resilient stenoses.
"Optimal blood flow dynamics are critical for maintaining treatment adequacy in patients with native AV fistulae of synthetic AV grafts. Nipro is committed to manufacturing products that give physicians the added tools necessary for procedural success and lower treatment times, minimizing post-procedural complications and bringing overall superior outcomes," said Joe Dawson, Senior Vice President for Nipro North America.
Cronus HP is a 0.035" guidewire system available in a wide range of lengths and diameters to treat focal, as well as diffuse AVF stenoses.
About Nipro Medical Corporation
Nipro Medical Corporation is a world-leading manufacturer of medical devices. The Company is committed to educating customers and delivering innovative, high-quality and value-added solutions to improve patient care. Nipro Medical Corporation is a wholly-owned subsidiary of Nipro Corporation, headquartered in Osaka, Japan.
Source: Nipro Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.